(4S)-2,2-dimethyl-4-(2-phenylethyl)-1,3-dioxolane | 157732-87-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (4S)-2,2-dimethyl-4-(2-phenylethyl)-1,3-dioxolane
• 英文别名: (4S)-2,2-dimethyl-4-phenethyl-1,3-dioxolane；(S)-2,2-dimethyl-4-phenethyl-1,3-dioxolane；(4S)-2,2-dimethyl-4-phenetyl-[1,3]dioxolane
• CAS: 157732-87-1
• 化学式: C₁₃H₁₈O₂
• 分子量: 206.285
• InChiKey: GFGHGHJRLCAOTC-LBPRGKRZSA-N

物化性质

• 沸点：
  277.7±15.0 °C(Predicted)
• 密度：
  0.994±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (4S)-2,2-dimethyl-4-(2-phenylethyl)-1,3-dioxolane 在 盐酸 作用下， 以 吡啶 、 甲醇 为溶剂， 反应 13.0h， 生成 (S)-2-hydroxy-4-phenylbutyl 4-methylbenzenesulfonate
  参考文献：
  名称：

  以声化学 Blaise 反应为关键步骤的 (+)- 和 (-)-Dihydrokavain 全合成

  摘要：

  以 2,3-O-异亚丙基-D-甘油醛 (2) 作为手性材料，以声化学 Blaise 反应为关键步骤合成天然存在的 (S)-(+)-dihydrokavain (1a) . (S)-(+)-dihydrokavain (1a) 的绝对构型首次通过手性来源的全合成得到证明。其相反的对映异构体 (R)-(-)-dihydrokavain (1b) 也是在 Mitsunobu 反应中手性中心反转后合成的。(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2005)

  DOI：

  10.1002/ejoc.200400833
• 作为产物：
  描述：

  苄基三苯基氯化膦 在 palladium on activated charcoal 正丁基锂 、 氢气 作用下， 以 甲醇 为溶剂， 生成 (4S)-2,2-dimethyl-4-(2-phenylethyl)-1,3-dioxolane
  参考文献：
  名称：

  Stereoselective synthesis of the 1,N2-deoxyguanosine adducts of cinnamaldehyde. A stereocontrolled route to deoxyguanosine adducts of α,β-unsaturated aldehydes

  摘要：

  alpha,beta-Unsaturated aldehydes (enals) react with deoxyguanosine and have mutagenic potential. For higher enals, the reaction of deoxyguanosine gives diastereomeric 6-substituted 8-hydroxypyrimidopurinone products. These stereoisomers may have different local conformations in DNA, which may have biological consequences. We have developed a stereospecific synthesis of 1, N-2-deoxyguanosine adducts of cinnamaldehyde. The key step is the synthesis is a metal-promoted intramolecular C-H insertion reaction of nitrogen of an enantiomerically pure sulfamate ester. The approach may be general for the stereocontrolled synthesis of this class of DNA adducts and can be applied to the preparation of site-specifically adducted oligonucleotides. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2003.08.006

文献信息

• Scope and Mechanism of the Pt-Catalyzed Enantioselective Diboration of Monosubstituted Alkenes
  作者：John R. Coombs、Fredrik Haeffner、Laura T. Kliman、James P. Morken

  DOI：10.1021/ja4041016

  日期：2013.7.31

  The Pt-catalyzed enantioselective diboration of terminal alkenes can be accomplished in an enantioselective fashion in the presence of chiral phosphonite ligands. Optimal procedures and the substrate scope of this transformation are fully investigated. Reaction progress kinetic analysis and kinetic isotope effects suggest that the stereodefining step in the catalytic cycle is olefin migratory insertion

  Pt 催化的末端烯烃的对映选择性二硼化可以在手性亚膦酸酯配体存在下以对映选择性方式完成。对这种转化的最佳程序和底物范围进行了充分研究。反应进程动力学分析和动力学同位素效应表明催化循环中的立体定义步骤是烯烃迁移插入 Pt-B 键。密度泛函理论分析与其他实验数据相结合，表明插入反应将铂定位在基板的内部碳上。该反应的立体化学模型得到了改进，该模型既符合这些特征又符合 Pt-配体复合物的晶体结构。
• A Total Synthesis of (+)- and (-)-Dihydrokavain with a Sonochemical Blaise Reaction as the Key Step
  作者：Fang-Dao Wang、Jian-Min Yue

  DOI：10.1002/ejoc.200400833

  日期：2005.6

  Starting from 2,3-O-isopropylidene-D-glyceraldehyde (2) as chiral material, the naturally occurring (S)-(+)-dihydrokavain (1a) was synthesized by a procedure that involves a sonochemical Blaise reaction as the key step. The absolute configuration of (S)-(+)-dihydrokavain (1a) is demonstrated for the first time by total synthesis from a chiral source. Its opposite enantiomer, (R)-(–)-dihydrokavain (1b)

  以 2,3-O-异亚丙基-D-甘油醛 (2) 作为手性材料，以声化学 Blaise 反应为关键步骤合成天然存在的 (S)-(+)-dihydrokavain (1a) . (S)-(+)-dihydrokavain (1a) 的绝对构型首次通过手性来源的全合成得到证明。其相反的对映异构体 (R)-(-)-dihydrokavain (1b) 也是在 Mitsunobu 反应中手性中心反转后合成的。(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2005)
• Phosphonoderivative of purine with antiviral activity
  申请人：Beecham Group p.l.c.

  公开号：EP0405748A1

  公开（公告）日：1991-01-02

  The (R)-isomer or the (S)-isomer of a compound of formula (IA), optionally in admixture with up to 45% of the mixture by weight of the corresponding (S)-isomer or the (R)-isomer respectively: wherein R₁¹ is hydroxy or amino; R₂¹ is amino or hydrogen; R₃¹ is hydroxymethyl or acyloxymethyl; and R₄ is a group of formula: wherein R₅ and R₆ are independently selected from hydrogen, C₁₋₆ alkyl and optionally substituted phenyl; or R₃ and R₄ together are: wherein R₆ is as defined above; having antiviral activity, a process for their preparation and their use in the treatment of viral infections or neoplastic diseases.

  化合物的(R)-异构体或(S)-异构体，其化学式为(IA)，可以与相应的(S)-异构体或(R)-异构体混合物以不超过45%的重量混合：其中R₁¹为羟基或氨基；R₂¹为氨基或氢；R₃¹为羟甲基或酰氧甲基；且R₄为以下式的基团：其中R₅和R₆分别独立选择氢、C₁₋₆烷基和可选取代的苯基；或R₃和R₄一起为：其中R₆如上定义；具有抗病毒活性，其制备方法及在治疗病毒感染或肿瘤性疾病中的应用。
• Total Synthesis of a Mevinic Acid Analog
  作者：Thummalapally Srikanth Reddy、Dorigondla Kumar Reddy、Manchala Narasimhulu、Dasari Ramesh、Yenamandra Venkateswarlu

  DOI：10.1002/hlca.201000062

  日期：2010.11

  Total synthesis of mevinic acid analog 1 has been achieved efficiently starting from chiral 2,3‐O‐isopropylidene‐D‐glyceraldehyde (2). The synthesis involves Mitsunobu reaction and Evans' intramolecular oxa‐Michael syn‐addition reactions as key steps.

  从手性2,3- O-异亚丙基-D-甘油醛（2）开始已成功实现了全酸类似物1的全合成。合成涉及Mitsunobu反应和Evans的分子内oxa- Michael合成加成反应作为关键步骤。
• PROCESS FOR PREPARATION OF 13,14-DIHYDRO-PGF2 ALPHA DERIVATIVES
  申请人：MARTYNOW Jacek

  公开号：US20080207926A1

  公开（公告）日：2008-08-28

  The invention relates to a process for the preparation of 13,14-dihydro-PGF 2α derivatives of R or S configuration at carbon 15, represented by the general formula (I), wherein the identity of the substituents is defined in the description. Compounds of the formula (I) are valuable biologically-active substances or intermediates in the preparation thereof. The invention especially relates to the process for preparation of 13,14-dihydro-15(R)-17-substituted-18,19,20-trinor-PGF 2α , i.e., latanoprost.

  本发明涉及一种制备在碳15处具有R或S构型的13,14-二氢-PGF2α衍生物的方法，该衍生物由通式（I）表示，其中置换基的身份在说明中定义。式（I）化合物是有价值的生物活性物质或制备中间体。本发明特别涉及制备13,14-二氢-15（R）-17-取代-18,19,20-三去甲-PGF2α，即拉坦前列素的方法。